Investor Relations

About Natera

Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health.

 

Our cutting-edge cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and AI, allowing detection down to a single molecule in a tube of blood. We’ve leveraged this platform to develop the most accurate non-invasive prenatal test on the market (Panorama™), the first tumor-specific assay for truly individualized cancer care (Signatera™), and best-in-class rejection assessment for kidney transplantation (Prospera™), among other transformative cfDNA tests.

 

Natera has performed more than 3 million cfDNA tests in its laboratories, more than any other, studied over 1.3 million patients and has been published in over 50 peer reviewed publications.

 
 
Natera San Carlos

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

September 17, 2021
Natera Releases New Clinical Data at ESMO 2021 in Gastroesophageal Cancer and Uveal Melanoma
Data suggests that ctDNA dynamics may be a better surrogate of overall survival than radiographic imaging (RECIST criteria) AUSTIN, Texas , Sept. 17, 2021 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a leader in cell-free DNA testing, today announced new data being presented by the company and its
September 9, 2021
Natera Launches Prospera™ Kidney with Quantification to Further Improve Test Performance, Demonstrating Commitment to Innovation in Transplantation
Validation study published in the Journal of the American Society of Nephrology (JASN) showed improved sensitivity with quantification vs. dd-cfDNA fraction alone AUSTIN, Texas , Sept. 9, 2021 /PRNewswire/ --   Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free
September 7, 2021
Natera's Signatera® Test Selected for NRG Oncology's Landmark CIRCULATE-US Study of MRD-Guided Treatment in Stage II-III Colon Cancer
Pivotal clinical trial aims to establish a new standard of care for stage II and III colon cancer patients AUSTIN, Texas , Sept. 7, 2021 /PRNewswire/ --  Natera, Inc.   (NASDAQ: NTRA) a leader in transforming care through genetic and cell-free DNA testing, today announced an agreement with NRG
August 31, 2021
Natera Announces the Validation and Launch of the Prospera™ Heart Transplant Assessment Test
Prospera Heart identifies rejection with exceptional performance from a single test, eliminating the need to combine two tests for each patient AUSTIN, Texas , Aug. 31, 2021 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA (cfDNA)
August 10, 2021
Natera to Participate in Upcoming Investor Conferences
AUSTIN, Texas , Aug. 10, 2021 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the company's leadership will participate in several upcoming investor conferences.     Steve Chapman , chief executive officer, and Mike Brophy,

Upcoming Events

More events are coming soon.

Past events